{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T16:45:24Z","timestamp":1794588324705,"version":"4.9.1"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Sarcomas are aggressive mesenchymal malignancies with high recurrence rates and poor prognosis, particularly in advanced, metastatic stages where conventional therapies have been exhausted. Fibroblast activation protein (FAP), highly expressed in the tumor microenvironment of sarcomas, presents a promising theranostic target. This study aimed to evaluate the safety and efficacy of \u00b9\u2077\u2077Lu-FAPI-2286 radioligand therapy (RLT) in patients with advanced metastatic sarcoma and to compare the diagnostic utility of \u2076\u2078Ga-FAPI-46 PET\/CT with \u00b9\u2078F-FDG PET\/CT in these patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This single-center exploratory study enrolled 6 patients (median age, 29\u00a0y) with histologically confirmed treatment-refractory metastatic sarcoma. All patients underwent baseline \u2076\u2078Ga-FAPI-46 and \u00b9\u2078F-FDG PET\/CT, followed by 2 to 4 cycles of \u00b9\u2077\u2077Lu-FAPI-2286 (3.7\u20137.4\u00a0GBq per cycle). Organ-level dosimetry was performed using serial planar and SPECT\/CT imaging. Treatment response was evaluated using PET response criteria in solid tumors (PERCIST), and toxicity was graded according to CTCAE v5.0. Quantitative image-derived metrics, including the standardized uptake value (SUV), metabolic tumor volume (MTV), total lesion glycolysis (TLG), FAP expression tumor volume (FTV), total lesion FAP expression (TLF), and tumor-to-liver ratio (TLR) were extracted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      On the basis of the quantitative imaging data from the 6 sarcoma patients, there was no statistically significant difference between \u2076\u2078Ga-FAPI-46 and \u00b9\u2078F-FDG across the measured parameters (SUV\n                      <jats:sub>mean<\/jats:sub>\n                      , SUV\n                      <jats:sub>max<\/jats:sub>\n                      , MTV\/FTV, TLG\/TLF, and TLR). However, \u00b9\u2078F-FDG showed slightly higher MTVs. RLT was well-tolerated, with no grade \u22653 treatment-related toxicities observed. Adverse events were limited to low-grade hematological toxicities, including grade 2 leukopenia (n=1), grade 1 anemia (n=2), and grade 1 thrombocytopenia (n=1). Among 6 patients, 3 died due to disease progression before follow-up imaging could be completed. Among the 3 evaluable patients, one patient showed a mixed response pattern with metabolic improvement, but volumetric progression [partial response (PR) based on a decrease in SUV\n                      <jats:sub>max<\/jats:sub>\n                      and SUV\n                      <jats:sub>mean<\/jats:sub>\n                      , progressive disease (PD) based on an increase in FTV, and stable disease (SD) based on minimal change in TLF], another patient showed SD, and the last patient demonstrated PD. The median overall survival was 4 months (95% CI: 0\u20138.8\u00a0mo).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>\n                      <jats:sup>177<\/jats:sup>\n                      Lu-FAPI-2286 RLT was safe, well-tolerated, and demonstrated disease stabilization in heavily pretreated sarcoma patients.\n                      <jats:sup>68<\/jats:sup>\n                      Ga-FAPI-46 PET\/CT provides superior delineation of FAP-rich tumor areas, but smaller tumor volumes compared with\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT. Prospective multicenter studies are warranted to confirm these findings and optimize FAP-targeted theranostic strategies in sarcoma.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/rlu.0000000000006507","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T15:07:13Z","timestamp":1777907233000},"page":"e739-e748","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["FAP-Targeted Theranostics in Advanced Sarcoma: A Pilot Study of \u2076\u2078Ga-FAPI-46 Imaging and \u00b9\u2077\u2077Lu-FAPI-2286 Therapy"],"prefix":"10.1097","volume":"51","author":[{"given":"Narges","family":"Jokar","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, The Persian Gulf Nuclear Medicine Research Center, The Persian Gulf Biomedical Research Institute, Molecular Imaging, and Theranostics, Bushehr Medical University Hospital, School of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malik E.","family":"Juweid","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Division of Nuclear Medicine, University of Jordan"},{"name":"The National Center for Diabetes, Endocrinology, and Genetics, University of Jordan, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9249-9248","authenticated-orcid":false,"given":"Esmail","family":"Jafari","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, The Persian Gulf Nuclear Medicine Research Center, The Persian Gulf Biomedical Research Institute, Molecular Imaging, and Theranostics, Bushehr Medical University Hospital, School of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7607-6859","authenticated-orcid":false,"given":"Elmira","family":"Yazdani","sequence":"additional","affiliation":[{"name":"Department of Medical Physics, School of Medicine, Iran University of Medical Sciences, Tehran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad A.","family":"Deylami","sequence":"additional","affiliation":[{"name":"Department of Hematology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed J.","family":"Rekabpour","sequence":"additional","affiliation":[{"name":"Department of Oncology, Salman Farsi Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5124-6380","authenticated-orcid":false,"given":"Nader","family":"Shakibazad","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology, Bushehr University of Medical Sciences, Bushehr"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milad","family":"Peer-firouzjaei","sequence":"additional","affiliation":[{"name":"Student Research Committee, Babol University of Medical Sciences, Babol, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6526-0960","authenticated-orcid":false,"given":"Hossein","family":"Arabi","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7559-5297","authenticated-orcid":false,"given":"Habib","family":"Zaidi","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, Switzerland"},{"name":"Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands"},{"name":"Department of Nuclear Medicine, University of Southern Denmark, Odense, Denmark"},{"name":"University Research and Innovation Center, \u00d3buda University, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2166-3765","authenticated-orcid":false,"given":"Majid","family":"Assadi","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, The Persian Gulf Nuclear Medicine Research Center, The Persian Gulf Biomedical Research Institute, Molecular Imaging, and Theranostics, Bushehr Medical University Hospital, School of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"R1-20260803","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.annonc.2021.07.006","article-title":"Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up(*)","volume":"32","author":"Gronchi","year":"2021","journal-title":"Ann Oncol"},{"key":"R2-20260803","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1016\/j.annonc.2021.08.1995","article-title":"Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"32","author":"Strauss","year":"2021","journal-title":"Ann Oncol"},{"key":"R3-20260803","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"68Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer","volume":"60","author":"Kratochwil","year":"2019","journal-title":"J Nucl Med"},{"key":"R5-20260803","doi-asserted-by":"crossref","first-page":"2480493","DOI":"10.1155\/2023\/2480493","article-title":"Fibroblast activation protein expression in sarcomas","volume":"2023","author":"Crane","year":"2023","journal-title":"Sarcoma"},{"key":"R6-20260803","first-page":"105","article-title":"Initial clinical experience using (68)Ga-FAPI-46 PET\/CT for detecting various cancer types","volume":"27","author":"Dadgar","year":"2024","journal-title":"Hell J Nucl Med"},{"key":"R7-20260803","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40336-023-00609-w","article-title":"Exploring the efficacy of FAPI PET\/CT in the diagnosis and treatment management of colorectal cancer: a comprehensive literature review and initial experience","volume":"12","author":"Dadgar","year":"2024","journal-title":"Clin Transl Imag"},{"key":"R9-20260803","first-page":"1689","article-title":"Targeting of fibroblast activation protein with [(161)Tb]Tb-FAP-2286 in treatment-refractory non-small cell lung cancer","volume":"53(3)","author":"Dash","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R10-20260803","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1007\/s00259-021-05273-8","article-title":"[(153)Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma","volume":"48","author":"Kratochwil","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R11-20260803","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1158\/1078-0432.CCR-22-1432","article-title":"Safety and efficacy of 90Y-FAPI-46 radioligand therapy in patients with advanced sarcoma and other cancer entities","volume":"28","author":"Fendler","year":"2022","journal-title":"Clin Cancer Res"},{"key":"R12-20260803","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1097\/RLU.0000000000003810","article-title":"Feasibility and therapeutic potential of 177Lu-fibroblast activation protein inhibitor-46 for patients with relapsed or refractory cancers: a preliminary study","volume":"46","author":"Assadi","year":"2021","journal-title":"Clin Nucl Med"},{"key":"R13-20260803","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2967\/jnumed.120.259192","article-title":"Feasibility, biodistribution, and preliminary dosimetry in peptide-targeted radionuclide therapy of diverse adenocarcinomas using 177Lu-FAP-2286: first-in-humans results","volume":"63","author":"Baum","year":"2022","journal-title":"J Nucl Med"},{"key":"R14-20260803","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.2967\/jnumed.119.239731","article-title":"Design and development of 99mTc-labeled FAPI tracers for SPECT imaging and 188Re therapy","volume":"61","author":"Lindner","year":"2020","journal-title":"J Nucl Med"},{"key":"R15-20260803","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2967\/jnumed.122.264544","article-title":"PET imaging of fibroblast activation protein in various types of cancer using 68Ga-FAP-2286: comparison with 18F-FDG and 68Ga-FAPI-46 in a single-center, prospective study","volume":"64","author":"Pang","year":"2023","journal-title":"J Nucl Med"},{"key":"R16-20260803","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00259-024-06795-7","article-title":"Feasibility and therapeutic potential of [(177)Lu]Lu-FAPI-2286 in patients with advanced metastatic sarcoma","volume":"52","author":"Banihashemian","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R17-20260803","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1007\/s00259-024-06809-4","article-title":"Evaluating [(225)Ac]Ac-FAPI-46 for the treatment of soft-tissue sarcoma in mice","volume":"51","author":"Taddio","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R18-20260803","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.7150\/thno.107963","article-title":"Targeted radioligand therapy: physics and biology, internal dosimetry and other practical aspects during (177)Lu\/(225)Ac treatment in neuroendocrine tumors and metastatic prostate cancer","volume":"15","author":"Dadgar","year":"2025","journal-title":"Theranostics"},{"key":"R19-20260803","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.mri.2012.05.001","article-title":"3D Slicer as an image computing platform for the Quantitative Imaging Network","volume":"30","author":"Fedorov","year":"2012","journal-title":"Magn Reson Imaging"},{"key":"R20-20260803","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1158\/0008-5472.CAN-18-0125","article-title":"LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity","volume":"78","author":"Nioche","year":"2018","journal-title":"Cancer Res"},{"key":"R21-20260803","doi-asserted-by":"crossref","first-page":"184001","DOI":"10.1088\/1361-6560\/ac8c83","article-title":"The OpenGATE ecosystem for Monte Carlo simulation in medical physics","volume":"67","author":"Sarrut","year":"2022","journal-title":"Phys Med Biol"},{"key":"R22-20260803","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors","volume":"50","author":"Wahl","year":"2009","journal-title":"J Nucl Med"},{"key":"R23-20260803","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.3390\/ph14121212","article-title":"First-in-human results on the biodistribution, pharmacokinetics, and dosimetry of [177Lu] Lu-DOTA. SA. FAPi and [177Lu] Lu-DOTAGA.(SA. FAPi) 2","volume":"14","author":"Ballal","year":"2021","journal-title":"Pharmaceuticals"},{"key":"R24-20260803","doi-asserted-by":"crossref","first-page":"880","DOI":"10.2967\/jnumed.123.267248","article-title":"(68)Ga-fibroblast activation protein inhibitor PET\/CT improves detection of intermediate and low-grade sarcomas and identifies candidates for radiopharmaceutical therapy","volume":"65","author":"Lanzafame","year":"2024","journal-title":"J Nucl Med"},{"key":"R25-20260803","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2967\/jnumed.118.210435","article-title":"A tumor-imaging method targeting cancer-associated fibroblasts","volume":"59","author":"Loktev","year":"2018","journal-title":"J Nucl Med"},{"key":"R26-20260803","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s13139-025-00936-y","article-title":"Exploring the diagnostic and theranostic role of FAPI PET in soft tissue sarcoma: a systematic review","volume":"59","author":"Abdulrahman","year":"2025","journal-title":"Nucl Med Mol Imaging"},{"key":"R27-20260803","first-page":"2271","article-title":"177Lu-FAP-2286 in patients with advanced or metastatic solid tumors: initial data from a phase 1\/2 study investigating safety, pharmacokinetics, dosimetry, and preliminary antitumor activity (LuMIERE)","volume":"63 (supplement 2)","author":"McConathy","year":"2022","journal-title":"Soc Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006507","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T20:01:50Z","timestamp":1785787310000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006507","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"2025-12-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}